FDA: AstraZeneca's Onglyza may increase death risk
This article was originally published in Scrip
Executive Summary
An FDA analysis of a cardiovascular outcomes trial (CVOT) conducted on AstraZeneca’s type 2 diabetes drug Onglyza (saxagliptin) found that the medicine appeared to increase the risk of death – news that caused the firm's shares to drop by 2% on 10 April.